Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $59M (up 10.3% year over year) with net income of $9M.
Q1 2026 key financials · XBRL
- Revenue
- $59M
- +10.3% YoY
- Net income
- $9M
- −24.4% YoY
- Operating margin
- 20.2%
- EPS (diluted)
- $0.44
- −30.2% YoY
Source: XBRL data from the RIGEL PHARMACEUTICALS INC (RIGL) Q1 2026 10-Q on SEC EDGAR. USD.
RIGEL PHARMACEUTICALS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $54.9M, up $11.3M or 26% YoY, based on TAVALISSE, REZLIDHIA, and GAVRETO sales
- Best performer TAVALISSE revenue $37.3M, up 31% YoY; worst performer GAVRETO revenue $9.6M, up 7%
- MDACC funding $5.3M through March 31, 2026; collaboration commitment $15.0M over five years
- Lilly termination effective June 15, 2026; no future milestones or royalties expected under the agreement
Risk Factors
- No newly marked risk factors; filing identifies no asterisked substantive changes from the December 31, 2025 Form 10-K
- GAVRETO boxed warning for serious infections, added December 22, 2025, heightening ongoing regulatory and compliance exposure
- Clinical development risk: July 2025 data correction reclassified an R289 patient from responder to non-responder
- Commercial risk: existing product sales remain highly dependent on successful commercialization in the US and international territories
- Manufacturing risk: reliance on third parties for commercial supply and distribution could interrupt product availability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RIGEL PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.